BioCryst Reports First Quarter 2008 Financial Results and Clini... (d pharmacokinetic profile of BCX-4208.Se...)

BioCryst Reports First Quarter 2008 Financial Results and Clinical Update

Date:5/8/2008

d pharmacokinetic profile of BCX-4208. Secondary objectives include assessment of pharmacodynamic measures and clinical response. The planned interim analysis of the Phase IIa trial included 30 patients divided evenly across the three study arms. The safety analysis includes follow-up on all 30 patients. Of the 30 patients evaluated for efficacy, 18 patients completed all 6 weeks of dosing. The 12 patients who discontinued prior to completing 6 weeks of dosing were equally distributed across the three arms of the study.

In an ongoing Phase I multiple ascending dose study, BCX-4208 showed a dose response effect on reducing lymphocyte counts at doses up to 1040mg administered once daily for 7 days. Interim data from the ongoing Phase IIa study at 20mg and 120mg showed similar dose-dependant effects on reduction of peripheral blood lymphocyte counts. Affected lymphocyte subsets in the Phase II study included CD4+, CD8+, CD56+, and CD20+ cells.

"While Roche's decision is disappointing, we are very encouraged by the effects on lymphocyte counts that we are seeing with BCX-4208. Similar activity with other experimental and marketed drugs has been associated with clinical efficacy in the treatment of various autoimmune diseases. Together with the good safety and tolerability profile of BCX-4208 observed to date, these data provide a strong scientific rationale for continuing to explore the activity of BCX-4208 in the treatment of autoimmune diseases," Mr. Stonehouse commented. "We look forward to evaluating the final data from the full cohort of 66 subjects later this year."

Conference Call and Webcast

The Company will sponsor a conference call at 8:30 a.m. Eastern Time on May 8, 2008 to discuss the financial results and the status of each of our programs in more detail. This call is open to the public and can be accessed live either over the Internet from http://www.biocryst.com or by dialing
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
2. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
3. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
4. BioCryst to Present at UBS 2007 Global Life Sciences Conference
5. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
6. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
7. Dendreon Reports First Quarter 2008 Financial Results
8. Nutrition 21 Reports Fiscal Third Quarter 2008 Financial Results
9. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
10. Oncothyreon Reports First Quarter 2008 Financial Results
11. iCAD Reports First Quarter 2008 Financial Results

Post Your Comments:

BioCryst Reports First Quarter 2008 Financial Results and Clini...(d pharmacokinetic profile of BCX-4208.Se...)